Prelude Therapeutics Incorporated
NASDAQ:PRLD
0.7069 (USD) • At close March 13, 2025
Overview | Financials
Numbers are in millions (except for per share data and ratios) USD.
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|---|---|
| Revenue
| 7 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue
| 0 | 1.169 | 3.042 | 2.243 | 0.542 | 0.382 | 0.149 |
| Gross Profit
| 7 | -1.169 | -3.042 | -2.243 | -0.542 | -0.382 | -0.149 |
| Gross Profit Ratio
| 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| Reseach & Development Expenses
| 117.995 | 103.393 | 92.889 | 86.778 | 48.177 | 24.279 | 12.621 |
| General & Administrative Expenses
| 28.719 | 28.884 | 30.651 | 26.957 | 10.586 | 3.83 | 2.354 |
| Selling & Marketing Expenses
| 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| SG&A
| 28.719 | 28.884 | 30.651 | 26.957 | 10.586 | 3.83 | 2.354 |
| Other Expenses
| 0 | -0 | 8.102 | 2.041 | 1.834 | 0.539 | 0.295 |
| Operating Expenses
| 146.714 | 132.277 | 123.54 | 113.735 | 58.763 | 28.109 | 14.975 |
| Operating Income
| -139.714 | -132.277 | -123.54 | -113.735 | -58.763 | -28.109 | -14.975 |
| Operating Income Ratio
| -19.959 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Other Income Expenses Net
| 12.541 | 10.445 | 8.102 | 2.041 | 1.834 | 0.539 | 0.295 |
| Income Before Tax
| -127.173 | -121.832 | -115.438 | -111.694 | -56.929 | -27.57 | -14.68 |
| Income Before Tax Ratio
| -18.168 | 0 | 0 | 0 | 0 | 0 | 0 |
| Income Tax Expense
| 0 | 0 | -8.102 | -0.915 | 0.336 | 0.21 | 0.295 |
| Net Income
| -127.173 | -121.832 | -107.336 | -110.779 | -56.929 | -27.57 | -14.68 |
| Net Income Ratio
| -18.168 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS
| -1.68 | -2.02 | -2.27 | -2.33 | -1.3 | -0.85 | -0.46 |
| EPS Diluted
| -1.68 | -2.02 | -2.27 | -2.33 | -1.3 | -0.85 | -0.46 |
| EBITDA
| -139.714 | -131.108 | -122.216 | -112.82 | -58.221 | -27.727 | -14.826 |
| EBITDA Ratio
| -19.959 | 0 | 0 | 0 | 0 | 0 | 0 |